Loco-regional administration of nanomedicines for the treatment of lung cancer

Abstract

Lung cancer poses one of the most significant challenges to modern medicine, killing thousands every year. Current therapy involves surgical resection supplemented with chemotherapy and radiotherapy due to high rates of relapse. Shortcomings of currently available chemotherapy protocols include unacceptably high levels of systemic toxicity and low accumulation of drug at the tumor site. Loco-regional delivery of nanocarriers loaded with anticancer agents has the potential to significantly increase efficacy, while minimizing systemic toxicity to anticancer agents. Local drug administration at the tumor site using nanoparticulate drug delivery systems can reduce systemic toxicities observed with intravenously administered anticancer drugs. In addition, this approach presents an opportunity for sustained delivery of anticancer drug over an extended period of time. Herein, the progress in the development of locally administered nanomedicines for the treatment of lung cancer is reviewed. Administration by inhalation, intratumoral injection and means of direct in situ application are discussed, the benefits and drawbacks of each modality are explored.

The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses

“…Many recent innovative studies have been conducted in this field and recently reviewed [14,19,20,25,26,27]. Here, we present what we consider to be the most promising technologies that take up the main challenges encountered in inhaled chemotherapy.…”

Nanomedicine-Based Inhalation Treatments for Lung Cancer

“…Large numbers of preclinical studies on designing tumor-targeting nanocarriers delivered by the pulmonary route have been described in the two last decades (Table 10.4). These studies are largely discussed in two reviews [53,54]. By far the greatest numbers of these nanocarriers have been developed as liquid nanosuspensions, i.e., adapted to nebulizers.…”

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants

“…High systemic doses of drug usually result in undesirable adverse effects to normal tissues (Saltzman & Fung, 1997 ). It is well known that traditional systemic chemotherapy employs high level of intravenous cytotoxic drugs and frequently causes severe systemic toxicity which limits the effectiveness and compromises the quality of life for patients (Goldberg et al., 2002 ; Garrastazu Pereira et al., 2016 ).…”